Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan Sells 15,000 Shares

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $108.32, for a total value of $1,624,800.00. Following the transaction, the director now directly owns 2,041,931 shares in the company, valued at approximately $221,181,965.92. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00.
• On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $107.12, for a total value of $1,606,800.00.
• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $101.68, for a total value of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.39, for a total value of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.54, for a total value of $1,628,100.00.

Moderna Stock Performance

NASDAQ:MRNA traded up $1.79 during mid-day trading on Friday, hitting $107.97. 2,245,667 shares of the stock were exchanged, compared to its average volume of 4,077,747. The stock has a market capitalization of $41.34 billion, a price-to-earnings ratio of -8.70 and a beta of 1.62. The firm’s 50-day simple moving average is $102.54 and its 200 day simple moving average is $93.77. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $142.79.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. During the same quarter last year, the company posted $3.61 EPS. The company’s revenue for the quarter was down 44.9% compared to the same quarter last year. As a group, equities analysts anticipate that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Moderna

A number of hedge funds and other institutional investors have recently bought and sold shares of MRNA. First Pacific Financial acquired a new position in shares of Moderna in the 3rd quarter valued at about $27,000. Ogorek Anthony Joseph NY ADV acquired a new position in Moderna during the 4th quarter worth approximately $27,000. Arlington Trust Co LLC raised its stake in Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares during the period. Westside Investment Management Inc. acquired a new position in Moderna during the 1st quarter worth approximately $32,000. Finally, Rise Advisors LLC raised its stake in Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after buying an additional 286 shares during the period. Institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the topic of several research reports. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. HSBC reissued a “reduce” rating and issued a $86.00 target price (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Jefferies Financial Group restated a “buy” rating and issued a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target for the company in a report on Tuesday, January 2nd. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $125.00 price objective on shares of Moderna in a report on Thursday, March 28th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $126.49.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.